Gilead voluntarily withdraws urothelial cancer drug in US

Forex Piața materiilor prime Piața bursieră Criptomonedă

(Reuters) - Gilead Sciences (NASDAQ:GILD ) said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.

Source: Investing.com

Publicații recente

Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy

24.01.2025 - 18:00

Crypto markets lose steam after Trump's first policy move

24.01.2025 - 18:00

Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson

24.01.2025 - 18:00

British American Tobacco, Altria shares rise after menthol ban proposal dropped

24.01.2025 - 18:00

Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%

24.01.2025 - 18:00

Commerzbank says no talks with UniCredit until specific proposal made

24.01.2025 - 18:00

Venture Global aims for $64 billion valuation at debut in test for energy IPOs

24.01.2025 - 18:00

Intuitive Machines stock surges on NASA contract award

24.01.2025 - 18:00

International Paper's $7.2 billion acquisition of DS Smith gets EU approval

24.01.2025 - 18:00

Short-term stock optimism soars among retail investors, AAII survey shows

24.01.2025 - 18:00

Venture Global shares likely to open up to 6% above IPO price

24.01.2025 - 18:00

Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers

24.01.2025 - 18:00

BMW joins Chinese EV makers in filing EU court challenge to tariffs

24.01.2025 - 18:00

Turkey stocks lower at close of trade; BIST 100 down 0.08%

24.01.2025 - 18:00

Diageo stock jumps on possible Guinness sale

24.01.2025 - 18:00

Analiza pieței Cum va afecta raportul NFP de mâine cursul de schimb al dolarului american?